Postorgasmic illness syndrome benefiting from omalizumab and antidepressant: a case report
The patient's symptoms improved significantly with the combination of omalizumab and escitalopram. This case not only provides a new perspective on the management of postorgasmic illness syndrome but also highlights the potential roles of allergic, psychiatric, and endocrinological mechanisms in the etiology and treatment of this complex condition.
Authors
- Nihal Mete (ORCID: https://orcid.org/0000-0002-2450-5439)
- Meryem Demir (ORCID: https://orcid.org/0000-0003-2915-6300)
- Mustafa Dinçkal (ORCID: https://orcid.org/0000-0003-4905-1602)
- Kasım Okan (ORCID: https://orcid.org/0000-0002-9743-4336)
- Sevgi Altay (ORCID: https://orcid.org/0009-0002-6042-7674)
- Ragıp Fatih Kural (ORCID: https://orcid.org/0000-0001-5690-4090)
- Furkan Cot
Institutions
- Ege University (TR)
Publication Details
- Journal
- Journal of Medical Case Reports
- Published
- 2024-12-21
- DOI
- https://doi.org/10.1186/s13256-024-04986-2
- Citations
- 1
- Primary Topic
- Sexual function and dysfunction studies
- Type
- article
- Field-Weighted Citation Impact
- 0.39